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ABSTRACT 
 
 This case-control study aimed to test for significant difference between the risks of 
suffering a cardiovascular event between two groups of moderate to severe psoriasis (PSO) 
patients: those that had a biologic therapy (BT) and those that did not.  The aim was to test for a 
protective factor in biologic therapies as patients with moderate to severe psoriasis have been 
reported to be at a higher risk of experiencing a cardiovascular event due to the chronic 
inflammatory nature of the disease. Cases were extracted from patient charts at Newlab Life 
Sciences, Inc. (NLS) and transferred to an electronic dataset, while controls were obtained from 
the Newfoundland and Labrador Centre for Health Information (NLCHI).  The results of a 
logistic regression failed to show a statistically significant relationship between the outcome, 
myocardial infarction (MI), and the use of a biologic therapy however, there was a protective 
trend for those patients on a biologic therapy.  There also appeared to be a relationship between 
age of onset and MI, as those patients diagnosed before the age of 25 saw a statistically 
significant greater risk of suffering an MI than those diagnosed after the age of 25. There were 
several limitations to this study including limited data and confounders, such as lifestyle factors 
and the change in price and availability of biologics to PSO patients over time. Based on the 
current literature limited evidence exists that supports the hypothesis that there is a significant 
protective factor associated with biologics in relation to cardiovascular events.   
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ORGANIZATION OF THE DISSERTATION 
 
 This Master’s thesis is presented in Chapters in order to keep the goals and objectives 
organized.  Chapter 1 reveals the topic of interest as well as providing a summary of the goal of 
the thesis; Chapter 2 provides background information including the prevalence and 
pathophysiology of psoriasis, a literature review describing treatment options, biologic therapies 
(BT) over time and how they are used today, as well as background on the association of 
myocardial infarction (MI) with psoriatic arthritis (PSA); Chapter 3 describes the materials and 
methods used; Chapter 4 presents the results of the statistical analysis (logistic regression) and 
presents relevant tables and graphs;  Chapter 5 is dedicated to the discussion of the results and 
how they relate to the literature available and concludes with a summary of  the strengths and 
weaknesses of the study.   
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CHAPTER ONE: INTRODUCTION 
  
This section introduces the topic of this thesis including the research question, the problem 
presented, and the goals and outcomes to be considered. 
 
Purpose 
The purpose of this study was to assess whether or not biologic therapies (BT) have a 
protective factor with respect to cardiovascular events, specifically MI, in patients with 
moderate to severe psoriasis. 
 
Objectives 
- To test for statistically significant relationships between the binary primary outcome MI 
and predictive factors such as BT use, age, age of onset, gender and smoking status.  
- To assess support for the continued use of BT in psoriasis patients. 
 
Research Questions 
- Does taking a BT play a role in the risk of experiencing an MI event? 
- Are there potential confounders? 
- Does PSO increase the overall risk of an MI event? 
- Does age of onset (defined as before or after the age of 25) play a role in increasing the 
risk of an MI event? 
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The Research Problem and Rationale 
 
Psoriasis is a relatively common auto-immune disorder associated with multiple 
co-morbidities and contributes to a significant economic burden (Gulliver et al., 2008).  
Co-morbidities include cardiovascular disease, psoriatic arthritis (PSA), ankylosing 
spondylitis, sacroiliitis, peripheral arthropathy, inflammatory bowel syndrome, 
dyslipidemia, type 2- diabetes (T2D), obesity, hypertension, metabolic syndrome and 
cutaneous t-cell lymphoma (CTCL) (Gulliver et al., 2011).  Due to the incurable and 
chronic nature of PSO, and the potentially devastating effects from the condition and co-
morbidities, a study like this is important as it may show a protective function of BTs. 
Given increasing evidence, BTs may become more readily prescribed and move towards 
more front-line status as a treatment option.   
 We are at an interesting position in time with respect to this study as BT as a 
treatment for PSO is relatively new.  These drugs only began gaining momentum in the 
early 2000s and have only been studied for the past decade (Baker and Coleman, 2012).  
In recent years researchers have been able to begin assessing the moderate to long term 
effects of these treatments and to start weighing the pros and cons of delivering BTs to 
patients.  Since BTs are becoming more accepted and their true effectiveness is gaining 
acceptance, insurance companies are more willing to provide coverage and the once hard 
to obtain BTs are becoming more accessible to PSO and PSA patients.  By gathering and 
analyzing data from PSO patient charts we can test to see if these drugs may also 
decrease the risk of MI.   
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CHAPTER TWO: LITERATURE REVIEW 
  
A literature search was conducted using PubMed and EMBASE databases in 2013 using 
the following search terms: psoriasis, psoriatic arthritis, biologic therapy, systemic therapy, 
methotrexate, cyclosporine, topical agent, UV therapy, cardiovascular disease, myocardial 
infarction and regression statistics. Using PubMed, the term ‘psoriasis’ was searched with filters 
to show only articles from the past ten years, for persons over the age of 18, full free articles, and 
from human species resulted in 1146 possible articles. After scanning titles and designs, 21 
relevant articles were chosen for review.  A second search using the same filters and the MeSH 
terms “psoriasis” and “biologic therapies” was conducted yielding 229 articles of which 9 were 
chosen based on a title scan. Finally, a third PubMed search was conducted using the MeSH 
terms “psoriasis” and “myocardial infarction” which returned 48 results. Of these, 41 were 
excluded based on title and/ or the abstract leaving 7.  Therefore, PubMed provided 37 of the 
articles used in this dissertation.  
 Using the EMBASE database, a search for “psoriasis” and “therapies” with filters 
including the date range 2003-2013, article design, 18 years of age and over, human only and 
English language returned 3517 articles of which 215 were selected based on a scan of the titles. 
Of these 215 abstracts, 54 articles were chosen for full review resulting in the inclusion of 21 
references for this study.   
In addition to online databases, a hand search was conducted of 2 physical publications of 
dermatology journals resulting in 3 reference papers.  
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PUBMED
N = 1146
(date: 02/23/13)
For detailed review  n = 86
Included
n = 37
Embase
N = 215
(date: 03/07/13)
Hand Search
N = 6
(date: 03/27/13
Included
n = 21
Excluded by title/abstract:
N = 1060
Excluded by title/abstract:
N = 161
For detailed review  n = 54
Total References
Used
n = 61
Included
n = 3
2.1 Inclusion/ Exclusion Criteria for Literature Review 
 
Articles chosen for this study were selected based on relevance and date (title and 
published within the past ten years).  To keep the focus of this review on the most current 
information, articles used to discuss the background/ pathology of psoriasis, therapies used, and 
psoriasis association with MI were from 2003 onwards.  No RCTs were found for this paper.   
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Overview of Systematic Literature Search 
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2.2 Psoriasis Overview 
  
Psoriasis is a chronic inflammatory disease which presents itself as scaly lesions (or 
plaques) on the skin and can have spontaneous flare ups and remissions (Xu, 2012).  
Approximately 2-3% of the population or about 125 million people globally are afflicted by the 
condition, resulting in US$4.3 billion per year in health care costs (Gulliver, 2011).  Although 
the etiology of the condition is not fully understood, evidence suggests that it has characteristics 
of an autoimmune disease with an inappropriate immune-mediated response. Psoriasis may also 
be dependent on a number of genetic and environmental factors.  Psoriasis is a heritable disease 
and as such is 4-6 times more likely to develop in first-degree relatives of individuals with 
psoriasis (Girolomoni, 2012).  
In patients with psoriasis, keratinocytes (the predominant epidermal cell) hyper-
proliferate due to faulty signaling from the immune system. This hyper-proliferation is driven by 
t-cell produced cytokines and chemokines such as inferon-ϒ, tumor necrosis factor α (TNF-α) 
and Interleukin 17A and 22 (IL-17A and IL-22) among others.  The over production of these 
cytokines amplifies the inflammatory response (as seen in psoriasis plaques) by causing the 
recruitment, retention and activation of immune cells in the skin (Girolomoni, 2012).  An 
increase in angiogenesis is also seen in psoriatic patients as a four-fold increase of the 
endothelial microvascular bed in psoriasis skin has been observed (Liew 2012).  This can present 
clinically as the “Auspitz’s sign” where psoriatic plaques bleed in a predicted manner when 
excoriated. 
 The disease can present itself with variable severity which can be effectively 
grouped into low, moderate or severe psoriasis based on the body surface area (BSA) affected. 
Low severity corresponds to ≤ 3% BSA coverage, moderate corresponds to 3-10% BSA 
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coverage and severe corresponds to a BSA coverage of ≥10%.  BSA is incorporated into the 
more rigorous Psoriasis Area and Severity Index (PASI) in order to generate a score reflecting 
severity, which is often used to monitor improvement of the condition over time under the effect 
of various treatment options. Most patients with PSO experience varying degrees of discomfort 
depending on severity (Langley, 2004). Since the mid-1990s, the dermatology life quality index 
(DLQI) is often used with the PASI score for the assessment of disease effect on day-to-day life 
for patients with psoriasis as well as other dermatological conditions (Finlay and Khan, 1994). 
Generally, a treatment is deemed moderately successful if a reduction of 50-74% in PASI score 
is seen (referred to as PASI 50), and a treatment is considered successful if the reduction in PASI 
score is 75% or more (referred to as PASI 75) (Banqueri 2012). Severity increase has been 
positively correlated with a 2-3 fold likelihood of mortality in severe psoriatic patients, with 
many reporting (>40%) that the condition adversely effects their daily routines (Gulliver, 2008). 
While lower health related quality of life (HRQoL) is valuable when studying the emotional 
effects of the disease on patients, it should not be used to diagnose severity due to the subjective 
nature of the measure (Girolomoni, 2012). The HRQoL tracks how an individual’s well-being is 
impacted by a condition over time by a disease and is often used in the form of a self-reported 
questionnaire (Reich 2012).  
 Numerous co-morbidities are associated with psoriasis including psoriatic arthritis in 5-
40% of patients (Weger, 2010) and depression (21-53% of patients) (Mrowitz, 2011; Fleming et 
al., 2014).  It has been debated whether or not psoriasis is linked to an increased risk of 
myocardial infarction (MI) given the hypothesis that the inflammatory nature of the disease 
would, over time, cause deterioration on the cardiovascular system due to long term xposure to 
inflammation. It has also been shown that psoriasis patients have a higher prevalence of other 
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traditional cardiac risk factors such as obesity, hypertension, diabetes, smoking, and metabolic 
syndrome all of which may act as confounding variables (Ahlehoff, Skov et al, 2012). Several 
hospital-based studies have found evidence supporting the hypothesis that psoriasis is an 
independent risk factor for incident MI with higher risk in younger patients with higher severity 
psoriasis (Reich, 2011). It is hypothesized that this can be attributed to the fact that patients 
whom are diagnosed earlier (under the age of 40) will have more time exposure to systemic 
inflammation and thus have a higher likelihood of suffering the adverse effects of the disease 
(Gelfand, 2006).   
There are presently multiple treatment options available for psoriasis. Traditionally 
milder psoriasis are treated with lower risk therapies such as phototherapy or topical 
corticosteroid (Akasaka, 2013).  More severe psoriasis may be treated with systemic therapies 
such as cyclosporine and methotrexate (Dogra, 2013).  Over the last decade biologic therapies 
(BTs) have gained momentum as a therapy of choice for PSO patients.  These agents are 
designed to target specific mediators in the immune response.  For example, Ustekinumab acts as 
an antagonist to IL-12 and IL-23 with the hopes of decreasing inflammation (Banqueri, 2012).   
It is hypothesized that these biologic therapies may also decrease the risk of major 
adverse cardiac events (MACE) such as MI, acute coronary syndrome and acute MI by 
decreasing the heightened pro-inflammatory response seen in psoriatic disease. Because these 
therapies are relatively new, studies are needed to determine the long term effects. Cohort studies 
and meta-analyses examining the effect of biologic therapies on MI risk were studied with no 
consensus yet reached (Abuabara et al, 2011; Ryan et al, 2011).  Due to the chronic long term 
nature of psoriasis, the potential cardio-protective benefits of biologic therapies may lead to a 
decrease in incident MI (Ahlehoff, 2012).  Given the complexity and the chronic nature of the 
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disease, long term, individualized treatment regimens taking MI risk factors into consideration 
should be implemented in psoriatic patients (Mrowietz, 2012).   
 
2.2.1 Mechanics of Psoriasis 
  
Psoriasis (PSO) can manifest in a number of forms including plaque psoriasis, which 
accounts for 80% of diagnosed PSO, making it the most common type and is characterized by 
scaly, erythematous plaques and has a relapsing and remitting course (Xu, 2012). Other types of 
psoriasis include pustular; a rare, particularly inflammatory erythrodermic form which can effect 
most of the body surface including the scalp. Nail psoriasis is also commonly seen in psoriatic 
patients (Akasaka, 2013).   
Once believed to be limited to the skin, more recent evidence indicates that PSO is a 
complex immune-mediated disorder. Due to erroneous immune signaling, keratinocytes in the 
skin hyper proliferate as a result of an overexpression of multiple chemokines, cytokines, and a 
reduction in t-cell regulation (Ahlehoff, 2011).  Cytokines are signaling molecules which can 
induce an inflammatory response in the skin whereas chemokines are a special subtype of 
cytokine with chemotaxic properties and recruit immune cells to the site of the inflammation 
(Xu, 2012). For example, the cytokine interleukin-17A (IL-17A), helps to protect the body 
against invading extracellular bacteria and fungi (Girolomoni 2012).  Neutrophils, mast cells, T-
helper 17 and Tc-17 cells produce IL-17A, all of which are found in psoriatic lesions (Duan et al, 
2001).  IL-17A will induce the production of antimicrobial peptides and pro-inflammatory 
cytokines which can lead to the hyper-proliferation of keratinocytes resulting is psoriatic plaques 
(Harper, 2009).  
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Another factor which is seen to be over expressed in psoriatic patients is the single 
stranded, non-coding micro RNA-31 (MiR-31). MiR-31 regulates a protein complex which 
controls DNA transcription known as nuclear factor kappa-light-chain-enhancer of activated B 
cells (Xu, 2012) which basically regulates the function and production of inflammatory 
mediators in the immune system.   
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2.2.2 Tumor Necrosis Factor Alpha (TNF-α) 
  
Tumor Necrosis Factor Alpha (TNF-α) is a cytokine associated with systemic 
inflammation and is mainly produced by macrophages.  It is believed to be a key moderator in 
psoriasis flare ups and may be caused by polymorphisms in the TNF-α gene leading to an over 
production of the cytokine (Prieto-Perez et al, 2013).  Upon activation, the macrophages release 
TNF-α at an altered rate in psoriatic patients causing an erroneous signal, resulting in an 
inflammatory response presenting as epidermal lesions.  In recent years anti-TNF-α therapies 
have been used alone or in combination with other systemic therapies, such as methotrexate, or 
topical creams, such as dovobet, as a way of repressing the over production of TNF-α with the 
hopes of decreasing symptoms and system inflammation (Thorlund et al, 2012).  These biologic 
therapies have proven to be effective although long term effects of TNF-α blockers are still under 
investigation. Certain cancers, as well as adverse skin conditions in the form of dermatitis and 
dermatosis, have been in seen in 10-60% of patients (Machado et al, 2013).  A study from Japan 
(Nakayama, 2013) suggests that anti-TNF-α therapies may contribute to autoimmune hepatitis 
but that study was a single case-study report.   
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2.2.3 Association with Myocardial Infarction (MI) 
  
PSO has long been understood to carry associations with numerous co-morbidities 
including diabetes mellitus, hypertension and dyslipidemia (Gulliver, 2008; Papp, 2013; 
Ahlehoff et al., 2011).  Patients with PSO have also shown higher prevalence of traditional risk 
factors for MI including obesity, stress, depression and smoking (Gelfand, 2006).  Recent studies 
now indicate that there is a measurable correlation between moderate to severe psoriasis and the 
risk of suffering an adverse cardiovascular event, although reports are still conflicting (Ahlehoff, 
2011).   Lin and associates conducted an analysis which suggests that some studies fail to find a 
correlation between psoriasis and an increased risk of MI but have failed to adjust for potential 
confounders and/or did not exclude patients with a previous history of MI. The majority of these 
studies focused on western societies which could be a limiting factor when trying to apply the 
results to a broader population (Lin, 2011).  The most commonly reported results indicate that a 
patient with PSO will have approximately a 2-fold increase in risk of suffering a MI when 
adjusted for traditional risk factors, suggesting that psoriasis is an independent risk factor for 
atherothrombotic disease, coronary artery disease and cardiovascular mortality (Papp, 2013; 
Xiao, 2009).  As previously noted, studies pertaining to this topic have varying results with odds 
ratios (OR) of suffering a MI being reported as low as 1.13 (95% CI: 1.08-1.18) and as high as 
6.48 (95% CI: 3.12-13.44)  (Papp, 2013).  It is now widely hypothesized that this inherent 
increase in MI risk in PSO patients may be due to the general inflammatory nature of TNF-α 
mediated diseases like psoriatic and rheumatoid arthritis (Gelfand, 2006).  Some suggest that 
treatments such as cyclosporin may also contribute to this elevated risk through higher blood 
pressure, hyercholesterolemia, triglyceridemia and low high-density lipo-protein cholesterol; all 
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traditional risk factors for MI (Xiao, 2009). Circulating endothelial cells (CEC) act as a marker 
of endothelial destruction in patients with atherosclerosis. Pro-inflammatory cytokines such as 
TNF-α,  IL-1β, IL-6 and IL-18, contribute to atherosclerosis by effecting pathophysiology of an 
inflammatory response. They cause the induction and maintenance of atherosclerosis factors 
such as hyperlipidaemia, insulin-resistance, adhesion of white cells to the endothelium, 
overexpression of some molecules, fatty streak formation and atherosclerotic plaque progression 
and rupture (Tam et al., 2013). An elevated number of CECs indicates a dysfunction in 
cardiovascular, hematological and/ or immune mediated inflammatory disorders (Batycka-Baron, 
2012). As well, the Von Willebrand Factor (vWf), a multimeric glycoprotein in blood plasma, 
acts as a marker for endothelial destruction.  Both CECs and vWf have been reported as elevated 
in psoriasis patients suggesting that damage to the circulatory system and the potential for 
suffering a MI is increased (Batycka-Baron, 2012).   
The heightened cytokine production in PSO patients increases the systemic inflammation 
(Reich, 2012). This can affect the migration of white blood cells to cause inflammation in both 
the skin and vasculature. Overall, it is reported that younger patients have a higher risk of 
suffering a MI because of the chronic nature of psoriasis (Xiao, 2009).  Papp and associates 
suggests that a 30 year old with severe psoriasis may have a relative risk (RR) of suffering an MI 
of 3.10 (95% CI: 1.98 - 4.86) (Papp, 2013).  Because of the conflicting results with respect to 
psoriasis as an independent risk factor for MIs, there is a need to better define ‘risk’ of 
cardiovascular disease to create a more standard practice as patients with psoriasis sometimes 
receive suboptimal cardio-protective care (Ahlehoff, 2011; Mrowietz, 2011).   
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2.2.4 Therapies  
  
Psoriasis (PSO) has an array of therapies which differ greatly in composition, function, 
risk and effectiveness. As previously noted, for milder psoriasis a topical ointment, a 
corticosteroid ointment (sometimes with a vitamin D analog added) or UV phototherapy may be 
prescribed; for moderate to severe psoriasis UV therapy may also be prescribed or a stronger  
systemic therapy such as methotrexate (MTX) or cyclosporin (both given orally) are viable 
treatments. Both of these therapies generally result in PASI 50 reached within 4-6 weeks, 
however they tend to have a higher risk profile including an increased risk of skin cancer, renal 
toxicity and arterial hypertension if therapy continues beyond two years (Mrowietz, 2013). In the 
past decade, a handful of biologic therapies including Humira (adalimumab), Remicade 
(infliximab), Stelara (ustekinumab) and Enbrel (etanercept) have been approved for the treatment 
of moderate to severe psoriasis. These organically derived therapies have been shown to have 
high effectiveness as a therapy for PSO (Reich 2012). It is important to note that long term risk 
profiles for these newer therapies are not yet known. The severity of the condition as defined by 
PASI, BSA and HRQoL may guide the physician to choose which therapy is best suited for the 
individual patient and depending on the individual, a combination of therapies may also be 
utilized (Takahashi, 2013).    
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2.2.4.1 Topical Ointments and UV Therapy 
  
Topical ointments have long been a standard therapy for PSO patients.  They tend to have 
a low risk profile and are ideal for patients who cannot tolerate the adverse effects or afford the 
cost of systemic therapies. Mild cases of PSO can generally be effectively controlled with a 
combination of lower risk topical corticosteroids and vitamin D3 analogs (Akasaka, 2013).  
Although they have lower risk associated with them, topical ointments can still lead to skin 
atrophy, tachyphylaxis and suppression of adrenal function after prolonged use (Akasaka 2013).   
 Nail psoriasis is a relatively common form of the disease effecting approximately 80% of 
all PSO patients at some point in their lives and is characterized by sore, raised nail beds (Huang, 
2013).  Generally, systemic therapies are not recommended for nail psoriasis because the 
potential risks are not justified.   
 By destroying t-cells and antigen-presenting cells in the skin, UV phototherapy is an 
often called upon therapy for PSO which sees remission in approximately 10% of patients with 
marked improvement seen in 40% (Akasaka, 2013).  Previously PUVA (psoralen plus UV) was 
the standard therapy; however increased efficacy has been shown in narrowband UV (NB-UV) 
therapy (Takahashi, 2013).  Potential adverse effects of stronger therapies like biologics are not 
observed in phototherapy meaning that it has a comparatively low risk profile.  
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2.2.4.2 Systemic Therapies 
  
Moderate to severe psoriasis may need a more rigorous therapy selection to control the 
disease (Reich, 2012).  Systemic therapies such as cyclosporin and methotrexate may carry a 
greater risk of adverse effects, but have shown consistently higher efficacy over UV 
phototherapy and topical corticosteroid ointments.  Cyclosporin, taken orally, generally 
generates quick improvement in erythema (Akasaka, 2013). Inhibiting t-cell function and pro-
inflammatory mediator production (such as IL-2) interferes with the immune response and 
decreases the presentation of skin lesions.  The standard initial dose of cyclosporin is 2.5-5mg/kg 
per day which generally sees clinically significant improvement after four weeks (Borhri, 2012).  
In approximately 20% of patients, nephrotoxicity is a potential adverse effect which is largely 
reversible upon therapy cessation (Sharma and Dogra, 2010).  One study aimed to find evidence 
of toxicity transferred to a patient’s offspring through breastfeeding.  Although the transfer of 
cyclosporin was evident via the breastfeeding method, it was in very small amounts with no 
adverse effects on the child (Mazzuoccolo, 2012).   
 Methotrexate (MTX), another oral systemic therapy for moderate to severe psoriasis, is 
commonly used once per week and is considered to be the gold standard therapy (Dogra, 2012; 
Elango, 2012).  Due to a higher risk profile, MTX use should be as limited as possible. Usually 
MTX is prescribed in a low dose and increased until significant improvement is recorded (Dogra, 
2013). Its primary function is to inhibit t-cell mediated inflammation by inhibiting the growth of 
keratinocytes, much like biologic therapies.  Interleukin-6 (IL-6) acts as a chemotactic factor for 
t-cells which stimulate migration to the epidermis as well as the growth and differentiation of 
dermal and epidermal cells (Elagno, 2012).  IL-6 can then be a marker for pathological processes 
associated with psoriasis.  Interestingly, one study showed that MTX may also decrease the risk 
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of experiencing a MI in PSO patients due to its suppression of the chronic inflammatory state 
(Prodanowich, 2005).   
 
2.2.4.3 Biologic Therapies  
  
Biologic therapies (BT) can be described as monoclonal antibodies made from organic 
materials such as recombinant therapeutic protein, somatic cells, tissues, viruses, blood 
components and allergenic materials.  Their primary mode of action is as a systemic component 
blocker as well as an anti-inflammatory. Different agents or BTs play different roles in PSO and 
PSA patients.  Adalimumab, for example, is a fully human monoclonal immunoglobulin G1 
antibody that neutralizes TNF by blocking its interaction with p55 and p75 TNF receptors on the 
cell’s surface, whereas Alefacept is a recombinant LFA-3-IgG1 fusion protein that binds to CD2 
on t-cells and blocks a co-stimulatory signal for memory effector t-cell activation (Castelo-
Soccio and Van Voorhees, 2009).  Some may be used to treat PSO and psoriatic arthritis (PSA) 
simultaneously while others, such as Efalizumab, are deemed effective for PSO but failed to 
show effectiveness for PSA. To date there are only a handful of these biologic therapies 
approved for this indication and  long term effects are still not completely understood.  Because 
there has yet to be a study directly comparing all agents the comparative efficacy is deduced 
from individual agent studies which aid the physician in making the best choice for an individual 
patient (Reich et al., 2011).  In one case four BTs were indirectly compared (Stelara, Humira, 
Remicade and Enbrel) using individual studies and no significant difference in efficacies were 
noted (Galvan-Banqueri et al., 2012). Some literature suggests that PSO patients receive 
suboptimal and disjointed care leading to a further diminution in QoL but with the addition of 
BT as a viable therapy option, a more individualized but standardized and efficacious algorithm 
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may be possible for patient care (Mrowietz et al., 2012).  As previously stated, after a decade of 
testing the potential long term effects are not yet fully understood, however there has yet to be 
any evidence of cumulative organ specific toxicity seen in patients taking a BT (Leonardi et al., 
2012).  A study looking at the long term effects of Uztekinumab through 3 years of follow-up 
found that adverse effects were comparable between a placebo group (50.4%), a group receiving 
45mg doses of the therapy (57.6%), and a group receiving 90 mg of the therapy (51.6%) with 
serious adverse effects remaining low across all groups (1.2-1.9%) (Lebwohl et al., 2011).  Due 
to reasonably high efficacy and apparently low incidence of adverse effects (or at least low risks 
of them occurring), at this point in time the benefit-to-risk ratio is considered acceptable (Weger, 
2010).   
 Biologic therapies are much more expensive than other regimes. A recent US based study 
using a commercial claims database from 2005-2009 describes health care costs of managing 
psoriasis on MTX and BT (Zhang and Hiscock, 2014). Analyzing 6,207 biologic patients they 
found that the average per annum health related costs for using a BT in psoriasis management 
was approximately $29,000.00 US. This is a steep price to pay for those without financial help 
(from insurance for example). A pharmacist at a local pharmacy in St. John’s, NL was able to 
comment on the cost of four BTs to psoriasis patients and the results are presented in table 2.1 
below. 
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Table 2.1: Cost of Four Commonly Prescribed Biologic Therapies in NL, Canada for One Year 
Agent Doses/ Year Cost of Dose Cost/ Year 
Humira ~ 24  $803 $19272 
Stellara 4 $5700 $22,800 
Enbrel 52-100 $438 $22,776 - $43,800 
Remicade* Highly Variable $4000-$5000 ~$29,000 - $39,000 
*Remicade is so variable because dose is based on body mass which differs between individuals and can fluctuate 
over time and infusion rate can vary from every 4 weeks to every 8 weeks. 
  
 
2.3 Literature on Biologic Therapies and Myocardial Infarction in PSO Patients 
  
A relatively new hypothesis is that BTs may have a cardio-protective factor in PSO 
patients due to their anti-inflammatory nature, leading to reduced inflammation around the heart 
and an overall reduction in stress on the heart.  As noted, those individuals diagnosed at an 
earlier age are seen to have a higher risk of suffering a myocardial infarction (MI) as the 
cumulative stress of PSO can play a destructive role on the cardiovascular system.  The majority 
of the literature on this topic suggested no detectable protective factor for BT on MI in PSO 
patients; however two recent studies reported a significant cardio-protective effect (Ahlehoff et 
al, 2012; Wu et al, 2012). 
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2.4 Summary of the Literature Review 
  
Psoriasis is a fairly common chronic autoimmune disorder with the most revealing 
symptom being scaly sore skin lesions.  Previously, the most common therapies, including 
PUVA, UV therapy and topical non-steroidal and steroid containing agents, target just the skin 
lesions..  For more severe cases systemic therapies such as methotrexate and cyclosporine may 
be used.  In recent years biologic therapies have become available and have proven to be 
effective with an acceptable benefit-to-risk ratio (although long term effects are still being 
studied).  Due to the chronic inflammatory nature of PSO, it is credited with contributing to 
multiple co-morbidities including cardiovascular disease.  An intriguing new hypothesis is that 
biologic therapies (BT) may provide protection against cardiovascular disease as they work 
systemically and have anti-inflammatory properties, although the current research has not been 
able to confirm that such a relationship exists.  
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CHAPTER THREE: MATERIALS AND METHODS 
 
3.1 Study Design 
  
This was an unpaired matched case-control study utilizing a mixture of physical patient 
charts and electronic hospitalization records to build a composite research dataset.  Once ethics 
and secondary use approvals were granted (see appendices E and F) the data was combined into 
one Statistical Package for Social Sciences (SPSS) file for analysis.  The cases were considered 
to be moderate to severe PSO patients (as determined by a dermatologist) taking a BT.  The 
control group were individuals with moderate to severe psoriasis not taking (nor had ever taken) 
a BT. 
3.2 Study Setting 
  
The study was conducted in St. John’s, Newfoundland and Labrador (NL) in Canada. 
Data came from two locations: Newlab Life Science, Inc. (NLS) and the Newfoundland and 
Labrador Centre for Health Information (NLCHI). The data from NLCHI came from a psoriasis 
research database as well as the clinical database management system (CDMS) which is a 
hospital discharge database. The CDMS database includes the variables MI (present or not 
present), number of MIs and date of admission to hospital for each event. Data for the control 
group came from randomly selected individuals from the psoriasis research database housed at 
NLCHI. This database includes about 3200 confirmed PSO patients in NL and includes date of 
birth, sex, age of onset, age of first dermatologic visit, severity of disease, and HLA-Cw6 
genotype status.  
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Data recorded at NLS and NLCHI also included the Medical Care Plan (MCP) number 
which was removed during the de-identifying process. The MCP number is held by all residents 
of NL and is their health insurance number. NLCHI also houses the Newfoundland and Labrador 
Medical Care Plan fee-for-service physician claims database which collects demographic and 
clinical information on services provided by physicians to patients in NL. The MCP number is 
heavily used in the province to identify individuals at hospitals, physician clinics and other 
electronic databases that house personal health information.   
 
3.3 Study Populations 
  
All patients in this study were classified by a dermatologist as having moderate to severe 
psoriasis (PSO).  Severity is determined by using the body surface area (BSA) – or the percent 
surface area of the body affected by the condition. The BSA is incorporated into the PASI score 
as discussed earlier.  The body is then separated into four areas: the head, the trunk, the arms and 
the legs. Each section is observed and given a score between 0 and 4 based on erythema 
(redness), induration (thickness) and desquamation (scaling), as well as the BSA. The score from 
the three factors are summed and multiplied by the score from the BSA and then by the weighted 
value given to each area (0.1 for the head, 0.2 for the arms, 0.3 for the trunk and 0.4 for the legs). 
As seen in figure 3.1, the final score can be between 0 (no PSO detected) and 72 (full body 
coverage and the most red, thickest and most scaly lesions).  
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  Figure 3.1: An example of an online PASI score calculator 
 
3.3.1 Cases: Patients Actively Taking a BT 
  
All patients selected at NLS were actively on a course of BT and were considered the 
case group. NLS is a medical and research clinic specializing in dermatology headed by Dr. 
Wayne P. Gulliver, MD, FRCPC. The case group included 178 patients taking or previously 
exposed to a BT.  Inclusion criteria included having moderate to severe psoriasis as clinically 
diagnosed by a dermatologist, over the age of 18, and able to give legal consent for their 
information to be used for research.  Since BTs are not prescribed to women who are pregnant 
(or goes into hiatus during pregnancy if a course of BT is already in progress) women who are 
pregnant were excluded from this study.  Patients with mild PSO severity were excluded as these 
patients would not have an acceptable benefit-to-risk ratio for BTs.  Since this study examines 
the protective factor of BTs in PSO patients, individuals in the case group having their 
myocardial infarction before the exposure to a BT were excluded from the final analysis. All 
patients included in this study (both cases and control) were from the province of NL.  PSO 
patients in the case group were all exposed at some point to least one BT for at least 1 month, 
some of which had gone through two, three or four BTs due to therapy switching.  
 
http://pasi.corti.li/ 
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3.3.2 Controls: Patients Not Taking/ Have Not Previously Taken a BT  
  
This group consisted of 561 patients who were not, or have never had a BT prescribed as 
a therapy.  As with the case group, all patients included were at least 18 years of age and legally 
able to consent to their information being extracted and used for research. Because these patients 
were not on a BT, pregnancy was not considered, however it should be noted that patients on 
methotrexate (MTX) are generally not prescribed the drug if they are pregnant. All patients in 
this group, as with the cases group, were clinically diagnosed with moderate to severe psoriasis 
by a dermatologist again excluding mild cases. When the request for data was made to NLCHI, a 
filter of patients seen in 2000 onwards was applied. The rationale behind this was to try to get a 
time line closely related to the BT group since PSO patients taking a BT would generally have 
been seen in the last ten years. Using the same time frame would also decrease confounding 
effects which may have been brought on by varying general diagnostic procedures, lifestyles and 
non-BT treatments occurring over time.  
 
3.4 Data Sources/ Data Linkage 
3.4.1 Newlab Life Sciences  
  
Data from NLS was extracted from physical patient charts and clinic letters through 
completion of a data collection sheet. Each patient file was filtered through and their age, date of 
birth, MCP number, age of onset, severity, BT type(s), duration on each BT (added together for 
total duration on BT) and smoking status (this variable was later excluded). The data was entered 
into a Microsoft Excel file and securely transferred to an employee of NLCHI for linking to the 
psoriasis research database (PRD) and hospital database (CDMS).  
3.4.2 Newfoundland and Labrador Centre for Health Information 
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An employee of NLCHI extracted data from the both electronic databases (PRD and 
CDMS) for linkage to the NLS data. Ethics and Secondary Use Committees granted approval for 
the data to be used in the study (see sections below).  Once approval was granted, the employee 
performing the data extraction and linkage was able to randomly select controls from the 
approximate 3200 confirmed psoriasis patients in the psoriasis research database.  561 controls 
were selected and matched to create a 3:1 ratio with respect to the cases (n=178) A 3:1 ratio was 
used to increase power since the primary outcome of MI was rare. 
 
 
3.4.3 Clinical Database Management System (CDMS) 
  
The CDMS is a provincial database collecting administrative, demographic and clinical 
data on patients’ hospitalization in NL health care facilities.  Data is collected by hospitals and 
forwarded to the Canadian Institute for Health Information (CIHI) which then populates the 
Discharge Abstract Database which is subsequently forwarded to NLCHI.  The CIHI derives 
information such as expected length of stay and resource intensity weights. Individual patients 
are assigned a unique code once gender, health care number (HCN), province issuing HCN and 
date of birth are confirmed. The CDMS is where the variables “hospital admission date” and “MI 
event” came from and they had to be specially requested in an amendment to the original 
secondary use application.  The CDMS has a comprehensive review and update cycle providing 
NLCHI with monthly cumulative updates and a year-end comprehensive file. NLCHI has had the 
responsibility of overseeing the CDMS for the Department of Health and Community Services 
since 1997.   
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3.4.4 International Classification of Disease Codes (ICD Codes) 
  
The ICD are a set of codes used for the systematic identification of conditions and were 
used in the primary extraction of variables for this project. ICD-9 codes represent the ninth 
revision of ICD and are numeric, whereas the ICD-10 (tenth revision) are recoded into an alpha-
numeric system.  ICD is an international standard for reporting clinical diagnoses and was 
developed by the World Health Organization. This project used IDC-10-CA which was 
developed by the Canadian Institute for Health Information as a means of enhancing the system 
for Canadian research. These codes were used for CDMS data extraction as they identified 
various types of MI in PSO patients.  
 
 
Table 3.1: ICD-9, ICD-10-CA Codes Used to Identify Myocardial Infarction Patients 
 Code Description 
 
ICD- 9 
410 Acute MI with stated duration of 8 weeks or 
less. 
412 Old MI: healed or prior MI diagnosed on ECG 
but currently presenting no symptoms. 
414.8 Chronic MI or with a stated duration of over 8 
weeks (8 weeks or older and patient is still 
symptomatic). 
 
ICD-10-CA 
I21 Acute MI 
I22 Subsequent MI (within 4 weeks) 
I25.2 Old MI: healed or prior MI diagnosed on ECG 
but currently presenting no symptoms. 
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3.4.5 Data Retention 
  
Destruction protocols will be adhering to Memorial University of Newfoundland’s 
(MUN) policies on data storage (and access).  Dr. Wayne P. Gulliver is the acting custodian of 
the Newlab Life Sciences dataset. The results will be stored for 5 years and destroyed following 
MUN policies for destruction which are available on the university’s website.  
 
3.4.6 Data Linkage 
 
 Data from NLS was sent to NLCHI via an encrypted secure file transfer and both sets 
were linked. An employee of NLCHI (not associated with the study) with clearance to access 
sensitive data randomly select patients from the psoriasis research database to include as 
controls. These patients were selected in a 3:1 (control: case) ratio and matched on age and 
gender to limit confounding effects.  Variables collected from the PRD were age, gender and age 
of onset.  Information on MI (hospitalization records), MI count and hospital admission dates for 
chronology of events were not recorded in the PRD at NLCHI but were recorded in the CDMS 
and was linked to the other two datasets forming the final dataset for this project. The variables 
case/control (to differentiate between cases, 1 and controls, 2) and ID were added.  ID is a 
numeric value used as an individual identifier as the final data set was de-identified. The 
researcher did not have access to the names and MCP numbers of those individuals included in 
data from NLCHI.  The final de-identified dataset was sent back to NLS using an encrypted file 
transfer and was stored on a secure desktop computer. 
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NLS Patient Chart Audits 
Performed by PI
Controls Randomly Selected from Psoriasis Research Database
Linkage of Hospitalization Data (CDMS)
Encrypted Secure File Transfer
Encrypted Secure File Transfer
Data De-identified
De-Identified Data Returned to NLS
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Pathway of Data between Centres 
 
3.5 Statistical Analysis 
 
All statistical analyses were conducted using IBM SPSS software (version 21, 2012) 
using a HP desktop computer using the Microsoft Windows XP operating system securely 
locked in a laboratory setting at NLS.  Once all data were linked and put into an excel 
spreadsheet it was transferred to SPSS for analysis.   
  Descriptive statistics were prepared using the descriptive statistics toolbar and calculated 
gender and age distributions, case to control ratio, age of onset including missing values and 
duration of treatment. 
Inferential statistics were run to test for significant relationships between variables using 
the binary MI (yes/no) as the primary outcome.  Since this outcome is binary, a logistic 
regression was performed. Individual relationships between cofactors and the primary outcome 
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were first tested by running a univariate regression for each cofactor.  The cases missing, 
omnibus test of model coefficients, model summary and final model tables are presented for each 
univariate regression.  A p-value ≤ 0.05 was used to test for statistical significance and odds 
ratios were extracted for the final model table.   
Once the univariate regressions were complete, a multivariate regression was completed 
presenting the same data as the univariate regressions and cofactors were tested for significance.  
To test for specificity and sensitivity of the model, a receiver operating curve (ROC) was 
produced and the area under the curve (AUC) was considered.  Next, to test for confounding 
multivariate collinearity, diagnostics were run to check all variance inflation factors (VIFs) and 
tolerances.  Finally, a case-control study sample size taking into account power and odds ratios 
was calculated using the program EpiInfo 7™ and a case/control relative risk was calculated by 
hand. 
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3.6 Ethical Considerations 
 
In order to obtain data from NLCHI, approval from the Health Research Ethics Board 
(HREB) under the Health Research Ethics Authority (HREA) was obtained.  HREA is the 
Newfoundland and Labrador ethics authority overseeing human research which aims to: 
“… ensure that health research involving human subjects is conducted in an ethical manner. 
To be responsible for enhancing public awareness of the ethical dimension of health research 
involving human subjects”. 
Following HREB approval NLCHI required the completion of a secondary use 
application.  This application was completed making requests for specific NLCHI data including 
the rationale behind why these variables were requested.  Once this application was approved by 
the Secondary Use Committee, NLCHI data was released for research purposes. 
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CHAPTER FOUR: RESULTS 
 
 The results of the statistical analysis will be presented in two sections: 
1. Descriptive Statistics: these statistics will include demographics such as age distribution 
and an MI summary, as well as biologic use patterns for the case group.   
2. Inferential Statistics:  a multivariate logistic regression testing for significant 
relationships between the binary primary outcome (MI event) and the cofactors.  
 
4.1 Descriptive Statistics 
  
This study contains 739 patients clinically diagnosed with moderate to severe psoriasis by 
a dermatologist; 463 males (62.7%) and 276 females (37.3%).  These patients came from NLS 
and from NLCHI.  Table 4.1 presents the baseline characteristics (age and gender) of patients 
from both NLS and NLCHI. Note, the cases and controls were matched based on age and gender. 
 
Table 4.1: Gender and Age Characteristics 
 Newlab Life Sciences Newfoundland and Labrador Centre 
for Health Information  
Male Female Male Female 
N=109 N=69 N=354 N=207 
 CASES CONTROLS 
Range  58 61 60 62 
Minimum  22 20 22 22 
Maximum  80 81 82 84 
Mean  52.6 49.6 52.9 50.0 
SD  11.0 12.3 10.9 12.4 
 
 The age of onset of psoriasis for both cases and controls were examined. This is a binary 
categorical cofactor describing the age at which patients were first diagnosed with their psoriasis. 
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Note that this is the age of clinical diagnosis as no data was available on whether or not patients 
self-reported earlier symptoms. In the literature there are discrepancies between what is 
considered “early onset”. Based on the numbers given, 25 years of age was chosen to be the 
threshold between early and late onset of psoriasis. Out of 739 patients, 121 (16.4%) were 
missing this data, all of which came from the control group leaving 440 controls with a known 
age of onset. 354 patients (85 cases and 269 controls) were considered to be early onset and 265 
patients (94 cases and 171 controls) were considered to be late onset.  
 Table 4.2 is a contingency table of age of onset distribution in the case and control 
groups. Since our controls were matched based on gender and age it would be advantageous to 
have equal prevalence of early and late onset of disease within both groups. After a chi square 
test was applied a chi square value of 4.13 with a p-value of 0.042 was the result meaning that 
the prevalence of early versus late onset of disease was un-evenly distributed between cases and 
controls.   
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Table 4.2: Contingency Table Showing Early and Late Onset of Psoriasis in the Case and 
Control Groups 
 Cases Controls Total 
≤ 25 93 269 362 
> 25 85 171 256 
Total  178 440 618 
*excluding the 121 missing values from the dataset 
 
The number of biologics taken by patients varied with switching generally being the 
result of an adverse event, treatment failure or lack of efficacy. As well the duration on any 
biologic in (months) varied across patients.  Since 32.6% of the patients were on the biologic for 
60 months or longer, it seems that if a therapy is efficacious for an individual they are more 
likely to remain on that therapy for a longer time without switching. Of the 178 cases, 139 were 
exposed to just one biologic, 28 patients had switched once meaning these patients had been 
exposed to two different biologic therapies (BT), 7 patients had switched twice exposing them to 
three different BTs. Finally, 2 patients switched three times meaning exposure to four different 
BTs.     
Table 4.3 below presents the 19 patients who have been admitted to hospital for an MI 
based on ICD-10-CA codes I21, I22 and I25.2 from the CDMS database.  Of the 19 individuals 
presenting with an MI, only 1 was from the case group (5.3%) and 18 were from the control 
group (94.7%).  The age range of those individuals suffering an MI in the control group was 51-
74 with a mean of 61.7 for males (SD = 6.2) and 62.3 for females (SD = 7.1). The single patient 
in the case group had just one myocardial infarction which occurred after exposure to a BT. In 
the control group, 12/18 (66.7%) had one MI event, 5/18 (27.8%) had two events and 1/18 
(5.6%) had five events.  
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Table 4.3: Characteristics of MI Patients 
 Case (n=1) Control (n=18) 
# of MI Events 
1 
2 
3 
5 
 
1 
0 
0 
0 
 
12 
5 
0 
1 
Gender M F M F 
1 0 14 4 
Age  
Range 
Mean 
SD 
 
NA 
NA 
NA 
 
- 
- 
- 
 
23 
61.7 
6.2 
 
15 
62.3 
7.1 
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4.2 Inferential Statistics 
4.2.1 SPSS Analysis 
 
Table 4.4 presents the variables used in the following regression analyses. Before the 
multivariate regression was undertaken, each co-factor was tested for a significant effect via 
univariate regressions. Table 4.5 presents the omnibus model test and the pseudo R-square 
values for the univariate analyses. The omnibus model test explains whether or not the explained 
variance in the model is greater than the unexplained variance. The value of significance is the 
probability of obtaining the chi-square statistic if there is no effect of the independent variables, 
taken together, on the dependent variable used to determine if the overall model is statistically 
significant. The pseudo R-squares (Cox & Snell and Nagelkerke) are used in logistic regression 
as it does not have an equivalent to the R-squared that is found in ordinary least squares 
regression. It is a relaxed approach to explaining the proportion of variance explained by the 
predictors. Table 4.6 shows the results of these univariate analyses and the odds ratios with their 
respective significance.  When tested individually, BT exposure did not show a significant 
relationship with MI outcome at the 0.05 level (p-value = 0.086) but was significant at the 0.10 
level. Duration on BT also failed to show significance (p-value = 0.183).  The co-factors that did 
show a significant relationship with MI were age, gender and age of onset with p-values of 
0.000, 0.018 and 0.005, respectively.  Males produced an odds ratio value of 3.6, meaning being 
a male increased the risk of suffering an MI by 3.6 times.  Age produced an odds ratio of 1.1 
suggesting that individuals are more likely to suffer an MI with each additional year of life 
added.  The greatest increase in odds ratio was age of onset with early onset attributing to a 
nearly 9 fold increase in risk of suffering an MI.  Of the two non-significant co-factors, BT 
exposure and duration, the univariate regression suggests that patients on a BT were 83% less 
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likely to suffer an MI than those not on a BT, which supports the alternative hypothesis that BT 
exposure would decrease the risk of an MI.  The duration of therapy seemed to minimally 
decrease the risk of MI with an odds ratio of 0.976 for each additional month of therapy added.   
Ho: Biologic therapies have no protective factor for MI events in PSO patients 
Verses 
Ha: Biologic therapies have a protective factor for MI events in PSO patients 
 
Table 4.4: Variables to be tested in the Regression Analysis 
 
Variable Type Description 
MI Binary (Dependent Variable) Whether or not a patient 
suffered an MI 
Age Continuous Age of patient in years 
Gender Binary Male or female 
Age of Onset Binary Diagnosis of PSA before or 
after the age of 25 
Case/ Control Binary Have or have not taken a BT 
Duration on 
Therapy 
Continuous Number of months on a BT in 
total 
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Table 4.5: Results of Univariate Regression Analyses (model tests and significance) 
Co-factor  Omnibus Model Test Pseudo R-Squared Values 
Chi-Square Sig Cox & Snell Nagelkerke 
Age 14.858 0.000 0.020 0.072 
Gender 7.348 0.007 0.010 0.036 
Age of Onset 25.645 0.000 0.040 0.149 
BT Exposure 5.029 0.025 0.002 0.008 
BT Duration 0.942 0.332 0.001 0.005 
 
 
Table 4.6: Results of Univariate Regression Analyses (Variable Significance and Odds Ratios) 
 
Co-Factor Odds Ratio Significance 
BT Exposure 0.170 0.086 
Gender (male) 3.643 0.018 
Age 1.072 0.000 
Age of Onset (early) 8.852 0.005 
Duration on BT 0.976 0.183 
 
 
  
The Multivariate Regression was carried out adding variables at the same time with the 
“enter method”.  The results show that only age of onset maintained statistical significance and 
BT exposure and duration maintained a lack of significance, however the age and gender 
variables were not significant when tested in the multivariate model.   Early age of onset 
maintained a higher risk of MI than late age of onset however the odds ratio decreased from 15.5 
to 11.2.  As seen in table 4.7, the multivariate model had an omnibus chi-square value of 24.9 
and a significance of 0.000 meaning that the model appears to be better than no model at all 
since there is a <5% chance that a chi-square value that high would be from chance alone.  The 
Cox and Snell R-square and the Nagelkerke R-Square values were reported as 0.04 and 0.2 
respectively loosely interpreted as approximately 20% of variation in the model being predicted 
by the variables entered into the model.  Table 4.8 outlines the final results of the multivariate 
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regression showing that only age of onset proved significant resulting in early onset contributing 
to about a 6.3 times increase in the likelihood of suffering an MI. Figure 4.2 presents a ROC 
Curve with an area under the curve (see figure 4.3) of 0.853 (95% CI: 0.0802 – 0.0903) 
suggesting that the model has high sensitivity (rate of true positive) and specificity (rate of true 
negative).  Finally, to test for collinearity, diagnostics were run to check the tolerance and 
variance inflation factors (VIF) of each variable.  As seen in table 4.9, all tolerances were over 
0.10 and VIFs were under 5 indicating that collinearity was within an acceptable range.   
 
Table 4.7: Multivariate Omnibus Test of Model Coefficients and R-Squares 
   
 Chi-square df Sig. Cox & Snell 
R Square 
Nagelkerke R 
Square 
 24.9 5 .000 0.039 0.203 
 
 
 
Table 4.8: Final Multivariate Logistic Regression Variable Significance and Odds Ratios 
 
Variable Odds Ratio Significance 
Sex (male) 3.952 0.078 
BT Exposure 0.070 0.300 
BT Duration 1.016 0.669 
Age of Onset 6.252 0.023 
Age 1.057 0.081 
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Figure 4.2: ROC Graph to test for Specificity and Sensitivity 
 
 
 
Area Under the Curve 
 
Area Std. Error
a
 Asymptotic Sig.
b
 Asymptotic 95% Confidence 
Interval 
Lower Bound Upper Bound 
.853 .026 .000 .802 .903 
The test result variable(s): Predicted probability has at least one tie between the 
positive actual state group and the negative actual state group. Statistics may be 
biased. 
a. Under the nonparametric assumption 
b. Null hypothesis: true area = 0.5 
 
Figure 4.3: SPSS Output for AUC Analysis 
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Table 4.9: Tolerance and VIF Values to Test for Collinearity in the Multivariate Logistic 
Regression Model 
 
Variable Tolerance VIF 
BT Exposure 0.353 2.834 
Gender 0.990 1.011 
Age 0.808 1.237 
Age of Onset 0.811 1.234 
Duration on BT 0.355 2.813 
 
 
 This analysis showed no statistically significant relationship between risk of suffering an 
MI and being placed on a BT. Subsequently, the duration on the BT failed to show statistical 
significance.  
 
4.2.2 Relative Risk Calculation and Sample Size Calculation 
4.2.2.1 Relative Risk Calculation 
  
The relative risk was calculated using the standard group exposure formula with 
subsequent confidence intervals and test statistic from the online software MedCalc 
(http://www.medcalc.org/calc/relative_risk.php).  This calculation was performed in order to 
give a ratio of the probability of an MI event occurring between the case and control groups. 
According to this calculation, patients on a BT had a lower risk (RR=0.176) of experiencing a 
myocardial infarction than the patients not on a BT. This finding supports the hypothesis that 
BTs have a protective effect for MI.  
 
 
RR = [1/(1+177)] / [18/(18+543)] 
RR = 0.176 
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Note: a = number of MI in Case Group, b = number of non- MI case group, c = number of MI control group, d = 
number of non- MI control group 
The 95% CI is: 
 
 
  
4.2.2.2 Sample Size Calculation 
 
Using EpiInfo version 7.0™ a sample size was calculated based on the odds ratio given 
that this study was a case/control study.  The final sample size with the Fleiss correction states 
843 cases are needed as well as 2528 controls.  The available data did not support that many 
cases.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
95% CI: (0.0198 to 1.0931), p = 0.0611 
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CHAPTER FIVE: DISCUSSION 
 
The discussion addresses four areas: 1) considers the results of this study and compares 
them to previous literature, 2) provides an overview of the strengths and weaknesses of this 
study, 3) suggests possible future study ideas that would better test the study hypotheses, and 4) 
summarizes the findings and conclusions. 
 
5.1 Discussion  
5.1.1 Comparing Results to the Literature 
  
This study aimed to detect a significant decrease in risk of suffering an MI in patients 
with moderate to severe psoriasis when taking a biologic therapy.  We looked at age, age of 
onset (defined as a PSO/PSA diagnosis before or after the age of 25 years), gender, whether or 
not the patient had been exposed to a BT at any point for at least 1 month, and the total duration 
of BT exposure.  Other potential confounders such as smoking status and diabetes status were 
considered for analysis but unfortunately no data was available. 
 Psoriasis has long been studied, yet its aetiology is not fully understood.  It has become 
more accepted that it is an auto-immune, systemic disorder rather than simply a skin oriented 
disease.  There is an array of therapies approved for PSO and PSA including topical agents, UV 
therapy, systemic therapies and anti-inflammatory therapies, however in the past decade biologic 
agents have gained momentum as a second-line therapy (Sharma & Dogra, 2010).  Studies such 
as this one may be used to move these BTs into a front-line therapy for PSO and PSA when 
severity warrants such a treatment.  It may be likely that these therapies shall take on a front-line 
role as the positive effectiveness is becoming more documented, understood and supported (Choi 
et al., 2014).  Even though biologic therapies show improved effectiveness there are noted trends 
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of treatment failure over time which results in BT switching (from etanercept to infliximab for 
example).  This leads to difficulty in ascertaining and attributing long-term effects to specific 
biologic therapies (Simard et al., 2011).  It is also important to remember that not all BTs work 
the same, as some act to block TNF-α while others inhibit IL-6, IL-12, IL-22 and/or IL-23 (and 
others). It may be difficult to choose the best BT for an individual patient (Mease, 2012), though 
anti-TNFs have a relatively safe profile thus far, even when other conditions are simultaneously 
occurring in a patient. Interestingly, a study by Tzellos et al (2013) found that those treated with 
IL-12/23 monoclonal antibodies, such as briakinumab, were at an elevated risk for MI but stated 
that mete-analysis on limited information may not be producing robust results. Senabra-Gallego 
et al (2013) studied etanercept and its long-term safety and efficacy outcomes finding that, after 
5 years of collecting data on patients being treated for ankylosing spondylitis, there was a 
favorable risk-benefit ratio with no significant cumulative toxicity. Laurenti et al (2013) tested 
for the safety of an anti-TNF (looking at potential liver damage) in patients infected with the 
hepatitis B virus and found the same stable conditions as those seen in non-hepatitis B patients. 
In comparison, Nakayama (2013) reported that 20 cases of patients taking TNF-α blockers were 
diagnosed with auto-immune hepatitis within weeks of starting their therapy. Machado et al 
(2013) found an increase in anaphylactic-type adverse effects in skin lesions in females in 
advanced age when taking TNF-α blockers.  Efficacy may be reported in a number of ways 
including the dermatology life quality index (DLQI), a simple questionnaire technique.  Patients 
answer questions based on their daily lives over the past week and a final score is given to 
represent the impact of PSO on the patients’ lives for that week. Scores range from 0 (no effect) 
to 30 (maximum impact) and over time can be used to track how well the patients are responding 
to any medication, or how the disease is progressing over time (Finlay & Khan, 1993).   
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 Psoriasis is associated with multiple co-morbidities of which one of the more serious is 
cardiovascular disease. Previous studies have shown a significant increase in risk of suffering an 
MI in PSO patients and is most likely attributed to the overall chronic inflammatory nature of the 
disorder. Since BTs act as a systemic therapy (injectable or intravenous infusion) which 
decreases inflammation in skin lesions, it is hypothesized that there may be a protective factor 
for cardiovascular disease as the BT would decrease inflammation on the cardiovascular system.  
Table 5.1 summarizes 5 pertinent papers discussing the association with BT in PSO patients and 
MI outcome.  Two of the papers failed to find a significant protective factor for MI in BTs.  Two 
papers claimed a reduced risk of MI in BT patients and one paper suggested a possible increase 
in MI in BT patients.  
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Table 5.1: Summary of Studies Searching for an Association between BT and MI Outcome 
Author(s) and Date Study Type Statistical Tests 
Conducted 
Association 
Between BT and MI 
Significant? 
Ryan et al (2011) Meta-Analysis of 
RCTs 
Absolute risk 
differences (two sided) 
None Detected 
 Abuabara et al 
(2011) 
Cohort Study Proportional hazards 
model controlling for 
confounders 
None Detected 
Tzellos et al (2012) Meta-Analysis of 
RCTs 
Odds Ratio Possible Higher Risk 
in BT Patients 
(IL12/23 blocker) 
 Ahlehoff et al 
(2012) 
Retrospective 
Longitudinal Cohort 
Study 
Chi-square and 2-sided 
t-tests for baseline 
characteristics, Cox 
regression model and 
sensitivity analysis 
Reduced Risk in BT 
Patients 
Jashin Wu et al 
(2012) 
Retrospective Cohort 
Study 
Chi-square and 
unpaired t-tests for 
baseline characteristics, 
Cox proportional 
hazards regression 
Reduced Risk in BT 
Patients (TNF-α 
blocker) 
 
 
 
5.1.1.1 Failed to Find a Statistically Significant Association 
  
In the Ryan et al study, 22 RCTs comprised of over 10,000 patients were analyzed testing 
for absolute risk differences. The BTs under investigation included IL-12/23 blockers and TNF-α 
blockers.  The primary outcome was the incident of MACE which encompasses MI, 
cerebrovascular accident and cardiovascular death.  The meta-analysis performed was unable to 
find a significant difference in MACE risk between BT and placebo groups but the authors state 
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that the study may be under powered due to the quality levels in the original RCTs included in 
the meta-analysis.   
 The Abuabara et al study used administrative and pharmacy claims data provided by a 
large US insurer.  It should be noted that Abuabara et al did not test BT specifically, but 
compared a placebo group to a group encompassing all systemic therapies (for example, BTs and 
methotrexate were combined).  This limits the generalizability of the study, however results may 
still prove useful as an overall comparison.  This study suggested a significant interaction for 
age, a known risk factor for MI.  In the systemic group there were 25,554 patients and in the 
control group there were 4,220 patients receiving UV therapy, however there was a chance that a 
small proportion for the control group were exposed to a BT at some point during their disease.  
After an adjusted proportional hazards model was conducted, no significant difference in risk 
was detectable.  In our study the logistic regression also was unable to detect any statistically 
significant differences between risks of MI in our cases versus the controls although a non- 
significant trend towards lower risk in the BT group was noted.   
 
5.1.1.2 Possible Higher Risk in BT Patients 
  
Even though the case/control groups did not differ significantly, there was a slight trend 
towards a decrease in risk of MI in the exposed to a biologic therapy group (Odds Ratio = 0.07, p 
= 0.300).  Tzellos et al (2012) found a differing trend in their study which examined a control 
group compared to patients taking an IL-12/23.  The final meta-analysis was carried out on 9 
RCTs based on their inclusion/ exclusion criteria.  The study makes a point to suggest that due to 
the ever increasing prevalence of BTs in the realm of PSO/PSA treatments, even the slightest 
statistical miscalculations may be amplified and adverse effects may be reported outside of the 
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clinical setting (meaning they may be missed in reports).  Furthermore, it is stated that risk 
differences for rare events produce very conservative confidence intervals leading to poor 
statistical power.  This is the case with this current study as well, given that out of the total 739 
patients included (both cases and controls combined) there were only 19 patients (2.6%) who 
experienced an MI (data extended back to the mid-1990s).   
 
5.1.1.3 Reduced Risk of MI in BT Patients  
  
Ahlehoff et al (2012) carried out a retrospective longitudinal cohort study looking at PSO 
patients on systemic treatments versus not on systemic treatments.  As with the Abuabara study, 
BTs and other systemic anti-inflammatories were combined and tested against patients using UV 
therapy and topical agents.  Therefore the results can only be loosely compared to this current 
study because, as identified in the methods section, BT patients were unique and other systemic 
therapies were combined with non-systemic (non-BT) therapies.  In the Ahlehoff study, 2,400 
patients were identified as being on a systemic therapy and hazard ratios were calculated to 
compare the groups.  The results showed a decrease in risk for systemic therapy patients after 
hazard ratios were adjusted for age, sex socio-economic status and co-morbities.  Sensitivity 
analysis supported this decrease in risk after the exclusion of patients with a history of 
hospitalization due to MI or having been on cardiovascular therapies, both being probable 
confounders.   
 Dr. Wu (2012) and colleagues compared the risks of patients on and not on TNF-α 
blockers for MI events.  Patient inclusion criteria included a diagnosis of PSO or PSA between 
the years 2004- 2010. It should be noted that during the univariate analysis, smoking status, 
methotrexate use, and obesity were not recorded as being statistically significant and were 
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dropped from the final analysis. Unfortunately there were no obesity or smoking data, and 
methotrexate use was absorbed in the “non-BT” group.  Once Dr. Wu et al completed a Cox 
proportional hazards regression using all significant variables stratified for age, the team found a 
54% reduction in hazard of incident MI.  
 The most significant and dramatic shift in OR for MI in this current study was seen in the 
“age of onset” variable.  The literature states a number of “cut-off points” to distinguish between 
early and late onset, with 40 years of age being the standard cut-off point, however data at NLS 
used 25 years of age. This is because although psoriasis can begin at any age, most people are 
diagnosed between 15 and 30 years of age and by age 40, most people who will get psoriasis will 
already have it (Horreau et al, 2013). It is believed that earlier onset of disease is associated with 
a family history of disease, increased severity, a stronger correlation to genetic allele positivity 
(HLA-C*06 for example) and increased risk of co-morbities including MI (Queiro et al., 2013).  
In our study, after a multivariate logistic regression as well as collinearity diagnostics, age of 
onset was associated with an OR = 6.3 (p-value = 0.023).   
 
 
 
 
 
 
 
 
 
 
 48 
 
5.1.2 Cost   
Table 5.2: Summary of Cost Analysis Papers 
Study and 
Date 
Was the 
economic 
question 
properly posed? 
Has the program’s 
effectiveness been 
validated? 
Measures for 
these costs and 
effects 
Were comparisons 
properly adjusted 
for time? 
Baojin Zhu 
et al (2013) 
Yes – aimed to 
evaluate health 
care costs for 
PSA patients on 
BT 
Yes - clinical 
support validating 
BT efficacy 
Payment 
history for PSA 
patients in the 
emergency 
department as 
well as the 
pharmacy 
Yes – PSA patient 
records from 2005-
2009 used 
Atsuyuki 
Igarashi et al 
(2013) 
Yes – cost and 
efficacy 
comparison for 
PSO patients 
BT efficacy 
supported 
Cost of BT 
calculated on 
approved 
dosing 
schedule using 
National Health 
Insurance listed 
drug price 
Yes – allowed for 
appropriate 
response times 
Christine 
Ahn et al 
(2013) 
Yes – Cost per 
patient achieving 
significant PSO 
improvement on 
BT 
Yes – States BTs 
since 2003 with no 
measureable 
cumulative toxicity  
Yes – based on 
2010 wholesale 
price of BTs 
and included 
physician visits 
and laboratory 
costs 
Yes – each patient 
was on BT for a t 
least 12 weeks  
Laura Bojke 
et al (2011) 
Yes – comparing 
costs of palliative 
care for PSA 
patients non- 
responsive to 
traditional 
therapies and 
those on BT 
Yes – states 
efficacy of BTs as 
patients reach PASI 
75 
Quality-
adjusted life 
years (QALY) 
to quantify cost 
and healthcare 
outcomes 
Yes – cohort tracks 
40 years of history 
in patients 
 
 Biologic therapies have traditionally been considered very expensive.  The general trend 
appears to be that as effectiveness and adverse effects become better understood, the cost has 
decreased and insurance companies have been approving more coverage for these therapies.  The 
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above table presents four cost-effectiveness studies on BT used by PSO and PSA patients and 
aims to evaluate the trends over time.   
 Zhu et al looked at the health care costs of PSA patients on BT using a cox proportional 
hazards model to evaluate time to discontinuation and logistic regression models were used to 
evaluate rate of BT switching. Costs were then compared between groups using propensity score 
adjusted bootstrapping methods. The study found that 67.7% of PSA patients used a BT as 
monotherapy while 32.3% used a BT in conjunction with other therapies such as topical agents.  
All-cause costs between BT monotherapy versus BT adjunctive therapy were not significantly 
different (approximately US$26,000 to $27,000 per year).  They found that 67.4% of PSA-
specific costs were accrued by pharmacy payments.   
 Igarashi et al compared cost-efficacy of BTs for PSO patients.  The study examined three 
BTs (infliximab, adalimumab and ustekinumab) and drug costs were calculated using the 
National Health Insurance drug price list which included re-imbursements.  Cost efficacy was 
compared by taking the annual drug acquisition cost divided by the mean probabilities of PASI 
response. PASI 75 weight-based efficacy was taken into consideration for validating the use of a 
BT. The lowest annual cost was for adalinumab in the first year at $23,995US (with second-best 
efficacy ratings) and the largest cost was for infliximab at $38,960US for the first year of 
therapy.  This shows the potentially large expense of undergoing a BT as well as the significant 
differences in costs between specific BT agents.  
 Ahn et al looked at cost effectiveness of BT for PSO patients as well but focused 
specifically on plaque psoriasis.  One year costs for patients reaching PASI 75 also seeing a 
significant improvement in their DLQI were calculated over a 12 week period and extrapolated 
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to get one year cost estimates. The study found infliximab to be the most cost effective and the 
most efficacious.   
 Finally, Laura Bojke et al composed a study looking at the cost-effectiveness of BTs for 
PSA patients.  A probabilistic cohort model was used to track PSA patients over 40 years – some 
of which ended up on a BT and the others did not.  Drug acquisition, application and monitoring 
costs were recorded based on pharmaceutical list prices.  The results show a total lifetime cost of 
approximately $67,000US for those patients not on a BT, about $106,000US for those who have 
taken adalimumab, $115,000US for those on etanercept and about $142,000US for those on 
infliximab. It appears that the cost – effectiveness is still difficult to ascertain for BTs as the 
literature is inconclusive using differing methods and reporting results do not appear to be 
uniform. 
 Coleman et al suggest that it is “important to consider all relevant factors in drug 
utilization and cost analyses because these new agents redefine efficacy, safety, and mode of 
drug delivery”.  It is also suggested that BTs are playing a larger role in the treatment of PSO and 
PSA, so more rigid, uniform and standardized cost analyses should be considered in the future.   
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5.2 Strengths of this Study 
  
This study involved a chart audit of available PSO patients on biologic therapies at 
Newlab Life Sciences, Inc. and controls from NLCHI to provide a 3:1 ratio in order to increase 
the power of this study as much as possible.  Since this study was a case-control study, it is more 
robust than a cross-sectional or case report study. In order to limit confounding as much as 
possible the controls were matched to the cases based on age and gender increasing the chances 
of detecting differences between the case and control groups based on our primary co-factors; 
Exposure at some point to a biologic therapy and the duration of the exposure.  Next, all patients 
were clinically diagnosed and followed by the same dermatologist.  Finally, due to an increase in 
availability to the general public based on financial and insurance reasons, BTs have become 
more readily prescribed meaning there was access to more patient information than would have 
been possible in the past.   
  
5.3 Limitations of this Study 
  
Being a case-control study, this study cannot provide evidence for causation. A 
randomized controlled trial (RCT) would be very costly and time consuming to conduct given 
the nature of the therapy and outcomes.  An RCT would more accurately measure longer term 
effects and potential cardiovascular – protective factors to the BTs but this goes beyond the 
scope of this M.Sc. thesis with limited time and no funding.  It must also be taken into 
consideration that the NL population is believed to have a higher prevalence in of psoriasis, 
upwards of 6%, compared to the global average of 2-3% (Gulliver et al., 2011).  Therefore 
results may not be generalizable outside the local community. As an extension of the previous 
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point, 100% of the patients in this study were of Caucasian descent limiting the extent that 
results could be generalized to other ethnicities.  
 In order to obtain sufficient power this study would have required approximately four 
times the number of available cases and controls.  Unfortunately, those numbers were not 
obtainable based on available data.  Next, one of the most significant variables, age of onset, was 
not recorded in patient charts for approximately 16% of the total sample size which lead to 
sample exclusion in the analysis.  Additionally, the original methods planned for this study 
involved looking at diabetes and smoking status for these patients.  Diabetes data was not 
obtainable and smoking status was extracted from NLS charts, however duration and amount of 
smoking as well as time since quitting (if the individuals had quit) was not available.  Therefore 
smoking status was only recorded for a portion of the NLS cases with simply yes or no status and 
no smoking data was available from NLCHI.  Another variable that was dropped was the 
severity of psoriasis (PSO). Initially the intention was to assess for MI outcomes based on mild, 
moderate or severe ratings of PSO.  Once charts were audited it was realized that mild patients 
were not included in BT studies or regimes and moderate to severe was grouped together as an 
umbrella term without being clearly differentiated.    
 In order to obtain the most accurate results the case and control group were matched 
based on age and gender as we were interested in any change in risk of suffering an MI.  Age of 
onset could not be matched but ideally would have equal prevalence of early and late onset of 
disease between the case and control groups. A simply chi square test showed that this 
distribution was significantly different with a p-value of 0.042.  
 Finally, it would have been beneficial to have other potential confounding data such as 
the presence of diabetes, weight/ obesity, diet, smoking and genetics to see whether or not these 
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variables had a significant impact on the outcome of MI events or were evenly distributed among 
cases and controls.  With respect to the case group, there was no data on pre-existing MI 
conditions (through confirmed prescriptions for cardiovascular drugs or physician visits) other 
than hospitalization dates for the MI event itself.   
 
5.4 Suggestions for Future Studies 
  
If a similar study question were to be undertaken, a retrospective or prospective cohort 
could be examined.  If multiple centres were recruited, the sample size could be significantly 
larger thus improving the likely of detecting differences if they truly existed.  The PI could 
compose a standardized data extraction form(s) to ensure that personnel carrying out the chart 
audits would know what to record and how to record it to create seamless uploading to an 
electronic database. An RCT may be ideal, however when the disease may be associated with a 
major adverse event, ethics approval may prove challenging and the cost to run such a study may 
be substantial.   
 Since the BT exposure showed significance at the 0.10 level when run in a univariate 
analyses, a more robust study may reveal more accurately the true nature of the relationship that 
biologic therapies have with PSO and cardiovascular degradation. A higher powered study 
would require a larger sample size as well as detailed data on possible confounders such as 
smoking history, family history of MI, personal history of MI, genetic predisposition (like the 
presence or absence of certain genes), obesity, dietary intake and activity rates to name a few.  
Statistical tests to see if these variables are normally and randomly distributed among the cases 
and controls would make the results much more accurate with higher power.  
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5.5 Conclusions 
  
This study had similar results to previous studies in relation to age of onset as a predictor 
of MI when a multivariate logistic regression was conducted.  As was expected, males were 
much more likely to suffer an MI than female patients and an early age of onset (defined as 
before or after the age of 25 years) contributed to a higher risk of MI, presumably due to a 
lengthier exposure to a chronic inflammatory state.  A significant relationship between age, BT 
exposure and duration of BT exposure was not detected, however a non-significant decrease in 
risk was seen in BT patients.  The results of this study showed an odds ratio of 0.07 with respect 
to odds of suffering a myocardial infarction with a p-value of 0.300. Although non-significant, 
the results suggest that biologic therapies may have a protective effect in chronic plaque psoriasis 
patients who are considered to be at a higher risk for MI than the general population.   
 The power of this study was a weakness and inability to detect statistically significantly 
differences may have been a result of the too small sample.  Missing data and the absence of 
expected explanatory variables information were additional problems associated with the study. 
It is also important to take note that biologic therapies are becoming more available over time as 
effectiveness and safety are becoming better understood. This leads to a higher prevalence of use 
and insurance coverage making it possible for more patients to have access to these therapies and 
the longer term therapeutic and adverse effects for PSO patients, including MI outcomes, may 
become easier to study.  
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APPENDICIES 
 
 
Appendix A: Data Dictionary 
 
Variable Name 
Variable 
Type 
Variable Description Values/format 
ID Numeric Randomly generated Record ID 
 
Case_Control_Group Numeric 
Variable to differentiate between Case and 
Control Group 
1 = Case 
2 = Control 
SEX String Sex of Patient 
F = Female 
M = Male 
Age Numeric Age of patient as of April 2014 
 
SEVERITY String Psoriasis severity 
 
Age_of_Onset_STR String Age of onset (String Variable) 
 
Age_of_Onset_Num Numeric Age of onset (Numeric Variable) 
1 = <= 25 
2 = > 25 
Biologic.1 String Name of first Biologic  treatment 
 
Start_Date.1 Date Start date of first Biologic treatment mm/dd/yyyy 
End_Date.1 Date End date of first Biologic treatment mm/dd/yyyy 
Duration_on_Treatment_.1 Numeric Duration of first Biologics treatment 
 
Biologic.2 String Name of second Biologic  treatment 
 
Start_Date.2 Date Start date of second Biologic treatment mm/dd/yyyy 
End_Date.2 Date End date of second Biologic treatment mm/dd/yyyy 
Duration_on_Treatment_.2 Numeric Duration of second Biologics treatment 
 
Biologic.3 String Name of third Biologic  treatment 
 
Start_Date.3 Date Start date of third Biologic treatment mm/dd/yyyy 
End_Date.3 Date End date of third Biologic treatment mm/dd/yyyy 
Duration_on_Treatment_.3 Numeric Duration of third Biologics treatment 
 
Biologic.4 String Name of fourth Biologic  treatment 
 
Start_Date.4 Date Start date of fourth Biologic treatment mm/dd/yyyy 
End_Date.4 Date End date of fourth Biologic treatment mm/dd/yyyy 
Duration_on_Treatment_.4 Numeric Duration of fourth Biologics treatment 
 
MI Numeric MI Event (Y/N) 
0 = No 
1 = Yes 
ADMIT_SERV_DTE.1 Date Admission date of first MACE event mm/dd/yyyy 
ADMIT_SERV_DTE.2 Date Admission date of second MACE event mm/dd/yyyy 
ADMIT_SERV_DTE.3 Date Admission date of third MACE event mm/dd/yyyy 
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Appendix B: Original Variable Request Table 
 
Case Group (Patient on Biologic Therapies)  
 
Name of Requested 
Database 
Variable(s) 
Requested 
Rationale Years Requested 
Clinical database 
management system 
Primary diagnosis 
of myocardial 
infarction (MI)  
To determine if patients were 
diagnosed with an MI to 
ultimately define relative 
risks on biologics compared 
to control group 
2000- 2013 
Clinical database 
management system 
Hospital admission 
date 
In addition to knowing 
whether or not a patient has 
suffered an MI, I need to 
know when as it will be 
important to differentiate 
whether or not the MI 
occurred before or after 
treatment start date.  
2000-2013 
Clinical database 
management system 
Hospital discharge 
date 
To see the outcome of the 
hospitalization (did the 
patient die or leave the 
hospital?)   
2000- 2013 
 Newlab psoriasis database Board certified 
classification of 
psoriasis severity 
Biologics are only prescribed 
to patients with a moderate or 
above severity of disease.  
2000-2013 
Clinical database 
management system 
De-identified code Case indicator 2000-2013 
Clinical database 
management system 
Sex Test for significance of 
gender on risk of primary 
diagnosis of MI 
2000-2013 
Clinical database 
management system 
Age Test for significance of age 
on risk of primary diagnosis 
of MI 
2000-2013 
Clinical database 
management system 
Age of onset Test for significance of length 
of disease presentation on risk 
of primary diagnosis of MI 
2000-2013 
Clinical database 
management system 
Treatment start date Serve as an indicator for 
hospitalized patients to tell if 
they suffered an MI before or 
after start of biologic therapy 
2000-2013 
Clinical database 
management system 
Treatment end date 
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Control Group (Patients not on Biologic Therapies) 
 
 
 
 
Name of Requested 
Database 
Variable(s) 
Requested 
Rationale Years Requested 
Clinical database 
management system 
Primary diagnosis 
of myocardial 
infarction (MI)  
To determine if patients were 
diagnosed with an MI to 
ultimately define relative 
risks on biologics compared 
to control group 
2000- 2013 
Clinical database 
management system 
Hospital admission 
date 
In addition to knowing 
whether or not a patient has 
suffered an MI, I need to 
know when as it will be 
important to differentiate 
whether or not the MI 
occurred before or after 
treatment start date.  
2000-2013 
Clinical database 
management system 
Hospital discharge 
date 
To see the outcome of the 
hospitalization (did the 
patient die or leave the 
hospital?)   
2000- 2013 
 Newlab psoriasis database Board certified 
classification of 
psoriasis severity 
To ensure that a comparable 
control group is sampled to 
compare to the patients on 
biologic therapies.  
2000-2013 
Clinical database 
management system 
De-identified code Case indicator 2000-2013 
Clinical database 
management system 
Sex Test for significance of 
gender on risk of primary 
diagnosis of MI 
2000-2013 
Clinical database 
management system 
Age Test for significance of age 
on risk of primary diagnosis 
of MI 
2000-2013 
Clinical database 
management system 
Age of onset Test for significance of length 
of disease presentation on risk 
of primary diagnosis of MI 
2000-2013 
Clinical database 
management system 
Treatment Type See trend in non-biologic 
therapies for moderate to 
severe psoriasis patients  
2000-2013 
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Appendix C: ICD-9/10 Codes for Myocardial Infarction 
 
ICD-9 and ICD-10-CA Codes 
Myocardial Infarction 
 
ICD-10-CA 
 
I21 Acute myocardial infarction 
 
I22 Subsequent myocardial infarction 
Note: For morbidity coding, this category should be assigned for 
infarction of any myocardial site, occurring within 4 weeks (28 days) 
from onset of a previous infarction 
 
I25.2 Old myocardial infarction 
Healed myocardial infarction 
Past myocardial infarction diagnosed by ECG or other special 
investigation, but currently presenting no symptoms. 
Note:  I25.2 would apply if a myocardial infarction when the MI 
occurred more than 4 weeks ago and the patient is not currently 
receiving treatment, observation or evaluation for the previous 
myocardial infarction. 
 
 
ICD-9 
 
410  Acute myocardial infarction 
- with a stated duration of 8 weeks or less 
 
412  Old myocardial infarction 
  - healed myocardial infarction 
- past myocardial infarction diagnosed on ECG or other special 
investigation, but currently presenting no symptoms 
 
414.8  Chronic or with a stated duration of over 8 weeks 
- this includes myocardial infarctions that are over 8 weeks old when 
the patient is still symptomatic; it also includes coronary insufficiency 
specified as chronic and myocardial ischemia not specified as acute 
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Appendix D: TCPA 2: CORE Certificate  
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Appendix E: Full HREB Ethics Approval 
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Appendix F: NLCHI Secondary Use Approval for Data Release 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
